Related Experiment Video
Updated: Mar 24, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
The Alzheimer's disease Aβ peptide binds to the anionic DMPS lipid bilayer
Christopher Lockhart1, Dmitri K Klimov1
1School of Systems Biology and Computational Materials Science Center, George Mason University, Manassas, VA 20110, United States.
Abstract:
We have applied isobaric-isothermal replica exchange molecular dynamics (REMD) and the all-atom explicit water model to study binding of Aβ10-40 peptide to the anionic DMPS bilayer. To provide comparison with a zwitterionic bilayer, we used our previous REMD simulations probing binding of the same peptide to the DMPC bilayer. Using two sets of simulations, we comparatively analyzed the equilibrium Aβ conformational ensemble, peptide-bilayer interactions, and changes in the bilayer structure induced by Aβ binding. Our results are six-fold. (1) Binding to the DMPS bilayer triggers the formation of stable helix in the Aβ C-terminal, although the helix-inducing effect caused by DMPS lipids is weaker than that of DMPC. (2) Compared to the DMPC-bound Aβ monomer, the anionic bilayer weakens intrapeptide interactions, particularly, formed by charged amino acids. (3) Binding of Aβ peptide to the DMPS bilayer is primarily governed by electrostatic interactions between charged amino acids and charged lipid groups. In contrast, these interactions play minor role in Aβ binding to the DMPC bilayer. (4) Aβ peptide generally resides on the DMPS bilayer surface causing relatively minor bilayer thinning. The opposite scenario applies to Aβ binding to the DMPC bilayer. (5) In contrast to DMPC simulations, Aβ largely expels anionic lipids from its binding "footprint" forming a ring of charged amino acids mixed with charged lipid groups around the peptide. (6) Aβ binding disorders proximal DMPS lipids more strongly than their DMPC counterparts. Our simulations show that Aβ monomers fail to perturb anionic or zwitterionic bilayers across both leaflets.
Insights
Amyloid-beta (Aβ) peptide binding to anionic DMPS bilayers differs significantly from zwitterionic DMPC bilayers, primarily driven by electrostatics and causing distinct structural changes in both the peptide and the lipid bilayer.
Area of Science:
- Biophysics
- Computational Chemistry
- Materials Science
Background:
- The interaction of amyloid-beta (Aβ) peptides with lipid bilayers is crucial for understanding neurodegenerative diseases like Alzheimer's.
- Previous studies have investigated Aβ binding to zwitterionic bilayers (DMPC), but interactions with anionic bilayers (DMPS) require further elucidation.
Purpose of the Study:
- To comparatively analyze the binding of Aβ10-40 peptide to anionic DMPS and zwitterionic DMPC bilayers.
- To investigate the impact of bilayer charge on Aβ conformation, peptide-bilayer interactions, and bilayer structural dynamics.
Main Methods:
- Isobaric-isothermal replica exchange molecular dynamics (REMD) simulations.
- All-atom explicit water model.
- Comparative analysis of Aβ conformational ensemble, peptide-bilayer interactions, and bilayer structural changes.
Main Results:
- Aβ binding to DMPS bilayers induces C-terminal helix formation, albeit weaker than with DMPC.
- Anionic bilayers weaken intrapeptide interactions and are primarily governed by electrostatic interactions.
- Aβ resides on the DMPS surface, expels anionic lipids, and disorders proximal lipids more strongly than DMPC.
Conclusions:
- Bilayer charge significantly dictates Aβ binding mechanisms and consequences.
- Electrostatic interactions are key drivers for Aβ binding to anionic bilayers.
- Aβ monomers do not perturb lipid bilayers across both leaflets, regardless of charge.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Dementia
The progression of dementia is generally gradual....

